Soft Tissue Sarcoma Market

  • Increasing prevalence of soft tissue sarcoma, rising Research and Development activities on drugs and other therapies, are some of the growth factors boosting the growth of the market. Soft tissue sarcoma is a type of cancer that grows from tissues such as nerves, muscles, fats, blood vessels, and thick skin tissues.
  • There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, Kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others. There are several drugs used for the treatment of soft tissue sarcomas such as sunitinib (Sutent), trabectedin (yondelis), sirolimus (Rapamune), bevacizumab (Avastin), doxorubicin (adriamycin), and others.


Soft Tissue Sarcoma Market Analysis

  • In Oct 2016, U.S. Food and Drug Administration approved Eli Lilly and Company’s drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types of soft tissue carcinoma.Clinical Trial Analysis:Total Soft Tissue Sarcoma Studies: 1567
  • By Disease Type, the market is segmented into Local sarcoma, Regional sarcoma, and Metastatic sarcoma. By treatment type, the soft tissue sarcoma market is segmented into radiation therapy, targeted therapy, chemotherapy, anti-angiogenesis drugs, and Others.
  • Chemotherapy has the largest market share in the soft tissue sarcoma market. Further, by End-user, the market has been segmented into hospitals, oncology centers, and Others. Hospitals are dominating the global soft tissue sarcoma market during the forecast period due to increasing number of patients getting treatment at hospitals for soft tissue sarcoma and other relevant cancers.


Global Soft Tissue Sarcoma Geography Shares

  • Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW. North America is leading the global soft tissue sarcoma market due to the high prevalence of cancer and soft tissue sarcoma. According to the American Cancer Society, there were more than 11,500 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. Asia-Pacific region is also growing due to rising awareness about increasing advanced treatments for cancer.
  • The major players of global Soft Tissue Sarcoma market include GlaxoSmithKline plc, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Genentech), Johnson & Johnson Services, Teva Pharmaceutical Industries Ltd Celgene Corporation, and others.
  • Some recently approved drugs for the treatment of Soft Tissue Sarcoma are:
  •  In June 2018, Taiwan Liposome Company, (TLC), a clinical-stage specialty pharmaceutical company declared the submission of an Investigational New Drug (IND) application with the U. S. FDA to initiate a Phase I/II, open-label, dose-escalation clinical trial of TLC178, a NanoX liposomal formulation of the anticancer drug vinorelbine, in pediatric rhabdomyosarcoma (a type of soft tissue sarcoma) patients.
  • The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.


Target Audience

  •  Raw Material Suppliers/ Buyers
  •  Product Suppliers/ Buyers
  •  Industry Investors/Investment Bankers
  •  Education & Research Institutes
  •  Research Professionals
  •  Emerging Companies
  •  Manufacturers


Why purchase the report?

  •  Visualize the composition of the Global Soft Tissue Sarcoma market across each indication, regarding type and applications, highlighting the critical commercial assets and players.
  •  Identify commercial opportunities in Global Soft Tissue Sarcoma by analyzing trends and co-development deals.
  •  Excel data sheet with thousands of data points of the Global Soft Tissue Sarcoma market – level 4/5 segmentation
  •  PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study
  •  Product mapping in excel for the critical Global Soft Tissue Sarcoma products of all major market players

Global Soft Tissue Sarcoma Market

Chapter 1. Soft Tissue Sarcoma Market – Methodology and Scope

1.1 Research methodology

1.2 Scope of the Report

Chapter 2. Executive Summary

Chapter 3. Industry Analysis

3.1 Market Drivers

3.2 Market Restraints

3.3 Porters Five Forces Analysis

3.3.1 Suppliers Power

3.3.2 Buyer Power

3.3.3 Industry Competition

3.3.4 Threat of new Entrant

3.3.5 Threat of Substitutes

 

Chapter 4. Global Soft Tissue Sarcoma Market – Epidemiology

Chapter 5. Global Soft Tissue Sarcoma Market -Product Pipeline Analysis

Chapter 6. Global Soft Tissue Sarcoma Market -Clinical Trail Analysis

Chapter 7. Segmentation by Disease Type

7.1 Local sarcoma

7.2 Regional sarcoma

7.3 Metastatic sarcoma

 

Chapter 8. Segmentation by Treatment

8.1 Radiation Therapy

8.2 Chemotherapy

8.3 Targeted therapy

8.4 Anti-angiogenesis drugs

8.5 Other Treatments

 

Chapter 9. Segmentation by End-User

9.1 Hospitals

9.2 Oncology Centers

9.3 Others

 

Chapter 10. Geographical Analysis

10.1 North America

10.1.1 United States

10.1.2 Canada

10.1.3 Mexico

10.1.4 Others

10.2 Europe

10.2.1 United Kingdom

10.2.2 Spain

10.2.3 Germany

10.2.4 France

10.2.5 Rest of Europe

10.3 Asia-Pacific

10.3.1 India

10.3.2 China

10.3.3 Australia

10.3.4 Japan

10.3.5 Rest of Asia-Pacific

10.4 South America

10.4.1 Brazil

10.4.2 Argentina

10.4.3 Rest of South America

10.5 Rest of the World

 

Chapter 11. Competitive Landscape

11.1 Market Share Analysis

11.2 Company Benchmarking

11.3 Key Strategies Adopted by Major Companies

 

Chapter 12 Company Profiles*

12.1 F. Hoffmann-La Roche Ltd.

12.2 GlaxoSmithKline Plc

12.3 Pfizer, Inc.

12.4 Johnson & Johnson Services, Inc.

12.5 Teva Pharmaceutical Industries Ltd.

12.6 Celgene Corporation

12.7 Bristol-Myers Squibb Company

12.8 Threshold Pharmaceuticals Inc.

12.9 Merck KGaA.

 

Chapter 12 Appendix

12.1 Sources

12.2 List of Tables

12.3 Expert Panel Validation

12.4 Disclaimer

12.5 Contact Us

 

List Of Tables

Table 1 Global Soft Tissue Sarcoma Market Value, By Therapy, 2018,2022 & 2026 ($ Million)

Table 2 Global Soft Tissue Sarcoma Market Value, By Disease Type, 2018,2022 & 2026 ($ Million)

Table 3 Global Soft Tissue Sarcoma Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 4 Global Soft Tissue Sarcoma Market Value, By Therapy, 2018,2022 & 2026 ($ Million)

Table 5 Global Soft Tissue Sarcoma Market Value, By Therapy, 2017-2026 ($ Million)

Table 6 Global Soft Tissue Sarcoma Market Value, By Disease Type, 2018,2022 & 2026 ($ Million)

Table 7 Global Soft Tissue Sarcoma Market Value, By Disease Type, 2017-2026 ($ Million)

Table 8 Global Soft Tissue Sarcoma Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 9 Global Soft Tissue Sarcoma Market Value, By Region, 2017-2026 ($ Million)

Table 10 North America Soft Tissue Sarcoma Market Value, By Therapy, 2017-2026 ($ Million)

Table 11 North America Soft Tissue Sarcoma Market Value, By Disease Type, 2017-2026 ($ Million)

Table 12 North America Soft Tissue Sarcoma Market Value, By Country, 2017-2026 ($ Million)

Table 13 South America Soft Tissue Sarcoma Market Value, By Therapy, 2017-2026 ($ Million)

Table 14 South America Soft Tissue Sarcoma Market Value, By Disease Type, 2017-2026 ($ Million)

Table 15 South America Soft Tissue Sarcoma Market Value, By Country, 2017-2026 ($ Million)

Table 16 Europe Soft Tissue Sarcoma Market Value, By Therapy, 2017-2026 ($ Million)

Table 17 Europe Soft Tissue Sarcoma Market Value, By Disease Type, 2017-2026 ($ Million)

Table 18 Europe Soft Tissue Sarcoma Market Value, By Country, 2017-2026 ($ Million)

Table 19 Asia-Pacific Soft Tissue Sarcoma Market Value, By Therapy, 2017-2026 ($ Million)

Table 20 Asia-Pacific Soft Tissue Sarcoma Market Value, By Disease Type, 2017-2026 ($ Million)

Table 21 Asia-Pacific Soft Tissue Sarcoma Market Value, By Country, 2017-2026 ($ Million)

Table 22 Middle East & Africa Soft Tissue Sarcoma Market Value, By Therapy, 2017-2026 ($ Million)

Table 23 Middle East & Africa Soft Tissue Sarcoma Market Value, By Disease Type, 2017-2026 ($ Million)

Table 24 GlaxoSmithKline: Overview

Table 25 GlaxoSmithKline: Product Portfolio

Table 26 GlaxoSmithKline: Key Developments

Table 27 Eli Lilly and Company: Overview

Table 28 Eli Lilly and Company: Product Portfolio

Table 29 Eli Lilly and Company: Key Developments

Table 30 Pfizer Inc.: Overview

Table 31 Pfizer Inc.: Product Portfolio

Table 32 Pfizer Inc.: Key Developments

Table 33 Bristol-Myers Squibb : Overview

Table 34 Bristol-Myers Squibb : Product Portfolio

Table 35 Bristol-Myers Squibb : Key Developments

Table 36 Roche Holding AG: Overview

Table 37 Roche Holding AG: Product Portfolio

Table 38 Roche Holding AG: Key Developments

Table 39 Johnson & Johnson Services: Overview

Table 40 Johnson & Johnson Services: Product Portfolio

Table 41 Johnson & Johnson Services: Key Developments

Table 42 Teva Pharmaceutical Industries Ltd : Overview

Table 43 Teva Pharmaceutical Industries Ltd : Product Portfolio

Table 44 Teva Pharmaceutical Industries Ltd : Key Developments

Table 45 Celgene Corporation: Overview

Table 46 Celgene Corporation: Product Portfolio

Table 47 Celgene Corporation: Key Developments

Table 48 Genentech USA: Overview

Table 49 Genentech USA: Product Portfolio

Table 50 Genentech USA: Key Developments

Table 51 Tracon Pharma: Overview

Table 52 Tracon Pharma: Product Portfolio

Table 53 Tracon Pharma: Key Developments

 

List Of Figures

Figure 1 Global Soft Tissue Sarcoma Market Share, By Therapy, 2018 & 2026 (%)

Figure 2 Global Soft Tissue Sarcoma Market Share, By Disease Type, 2018 & 2026 (%)

Figure 3 Global Soft Tissue Sarcoma Market Share, By Region, 2018 & 2026 (%)

Figure 4 Global Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 5 Global Soft Tissue Sarcoma Market Y-o-Y Growth, By Therapy, 2018-2026 (%)

Figure 6 Surgery: Global Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 7 Radiation therapy : Global Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 8 Chemotherapy: Global Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 9 Global Soft Tissue Sarcoma Market Y-o-Y Growth, By Disease Type, 2018-2026 (%)

Figure 10 Local sarcoma: Global Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 11 Regional sarcoma: Global Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 12 Metastatic sarcoma: Global Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 13 Global Soft Tissue Sarcoma Market Y-o-Y Growth, By Region, 2018-2026 (%)

Figure 14 North America Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 15 North America Soft Tissue Sarcoma Market Share, By Therapy, 2018 & 2026 (%)

Figure 16 North America Soft Tissue Sarcoma Market Share, By Disease Type, 2018 & 2026 (%)

Figure 17 North America Soft Tissue Sarcoma Market Share, By Country, 2018 & 2026 (%)

Figure 18 South America Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 19 South America Soft Tissue Sarcoma Market Share, By Therapy, 2018 & 2026 (%)

Figure 20 South America Soft Tissue Sarcoma Market Share, By Disease Type, 2018 & 2026 (%)

Figure 21 South America Soft Tissue Sarcoma Market Share, By Country, 2018 & 2026 (%)

Figure 22 Europe Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 23 Europe Soft Tissue Sarcoma Market Share, By Therapy, 2018 & 2026 (%)

Figure 24 Europe Soft Tissue Sarcoma Market Share, By Disease Type, 2018 & 2026 (%)

Figure 25 Europe Soft Tissue Sarcoma Market Share, By Country, 2018 & 2026 (%)

Figure 26 Asia-Pacific Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 27 Asia-Pacific Soft Tissue Sarcoma Market Share, By Therapy, 2018 & 2026 (%)

Figure 28 Asia-Pacific Soft Tissue Sarcoma Market Share, By Disease Type, 2018 & 2026 (%)

Figure 29 Asia-Pacific Soft Tissue Sarcoma Market Share, By Country, 2018 & 2026 (%)

Figure 30 Middle East & Africa Soft Tissue Sarcoma Market Value, 2017-2026 ($ Million)

Figure 31 Middle East & Africa Soft Tissue Sarcoma Market Share, By Therapy, 2018 & 2026 (%)

Figure 32 Middle East & Africa Soft Tissue Sarcoma Market Share, By Disease Type, 2018 & 2026 (%)

Figure 33 GlaxoSmithKline: Financials

Figure 34 Eli Lilly and Company: Financials

Figure 35 Pfizer Inc.: Financials

Figure 36 Bristol-Myers Squibb : Financials

Figure 37 Roche Holding AG: Financials

Figure 38 Johnson & Johnson Services: Financials

Figure 39 Teva Pharmaceutical Industries Ltd : Financials

Figure 40 Celgene Corporation: Financials

Figure 41 Genentech USA: Financials

Figure 42 Tracon Pharma: Financials


Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report